ProMis Neurosciences, Inc.
1920 Yonge Street
103 articles with ProMis Neurosciences, Inc.
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
ProMIS Neurosciences, Inc. today announced its operational and financial results for the three and nine months ended September 30, 2018.
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer.
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of novel targets on misfolded, pathological forms of tau.
Unique discovery platform generates new antibody candidates that block a root cause of Parkinson's Disease
The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
ProMIS Neurosciences, Inc. today announced it has issued a narrated overview of second quarter 2018 operational results.
ProMIS Neurosciences, Inc. announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Lack of PMN310 binding to amyloid deposits in Alzheimer's brain tissue may eliminate dose-limiting brain swelling seen with BAN2401 and aducanumab
The net loss for the three months ended June 30, 2018 was $2,214,861, compared to a net loss of $1,903,396 for the three months ended June 30, 2017.
ProMis Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a narrated commentary on key lessons from this year's Alzheimer's Association International Conference (AAIC).
Key conference theme: targeting toxic amyloid-beta oligomers offers renewed hope for treatment of Alzheimer's disease
ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity
ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease
ProMIS Neurosciences, Inc. announced the initiation of producer cell line development for PMN310
ProMIS is a company focused on the discovery and development of precision treatments for neurodegenerative diseases
Financing will allow continuation of lead program targeting a root cause of Alzheimer's disease.
ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2017.
ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
The warrants were exercised at $0.17, $0.20 or $0.30.
ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”
This is one of a series of commentaries from the ProMIS scientific team offering insight on Alzheimer’s disease (AD) science and the Company’s emerging product portfolio.